Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
94
Active, not recruiting, industry sponsors, Neurology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting104
- Completed1,034
94 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04035005 · 1,013 participants · Start Aug 12, 2019 · Primary completion Jan 15, 2025
Drug: Ocrelizumab; Placebo · For: Multiple Sclerosis, Primary Progressive
Sites: Washington D.C., District of Columbia; Clearwater, Florida; Orlando, Florida · 153 sites in all
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersPivotal-lookingActive, not recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05152147 · 920 participants · Start Dec 2, 2021 · Primary completion Jul 15, 2026
Drug: Zanidatamab; Tislelizumab and 5 more · For: Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Pergamino, Argentina · 227 sites in all
- A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADPivotal-lookingActive, not recruiting
Annovis Bio Inc.Industry
NCT06709014 · 861 participants · Start Feb 4, 2025 · Primary completion Dec 2027
Drug: buntanetap/posiphen; Placebo · For: Early Alzheimers Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 78 sites in all
- A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With SeizuresPivotal-lookingActive, not recruiting
NCT04715646 · 84 participants · Start Mar 11, 2021 · Primary completion Jul 8, 2030
Drug: Brivaracetam · For: Epilepsy
Sites: Hawthorne, New York; Durham, North Carolina; Budapest, Hungary · 32 sites in all
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Pivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06696443 · 455 participants · Start Dec 18, 2024 · Primary completion Jan 25, 2027
Drug: Suzetrigine · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Daphne, Alabama; Scottsdale, Arizona · 65 sites in all
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisPivotal-lookingActive, not recruiting
SandozNovartis (NVS)
NCT06847724 · 183 participants · Start Jun 10, 2025 · Primary completion Nov 3, 2026
Drug: CYB704; Ocrevus-EU and 1 more · For: Relapsing Multiple Sclerosis
Sites: Maitland, Florida; Ormond Beach, Florida; Banja Luka, Bosnia and Herzegovina · 41 sites in all
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05156281 · 1,007 participants · Start Dec 13, 2021 · Primary completion Jul 22, 2026
Drug: Remibrutinib; Teriflunomide · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Hanford, California; Los Angeles, California · 223 sites in all
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04544436 · 864 participants · Start Nov 26, 2020 · Primary completion Dec 19, 2024
Drug: Ocrelizumab; Ocrelizumab and 2 more · For: Multiple Sclerosis
Sites: Cullman, Alabama; Homewood, Alabama; Phoenix, Arizona · 121 sites in all
- Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06141486 · 943 participants · Start Dec 27, 2023 · Primary completion Mar 24, 2028
Drug: Frexalimab; Placebo and 1 more · For: Multiple Sclerosis
Sites: Homewood, Alabama; Scottsdale, Arizona; Berkeley, California · 311 sites in all
- An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisPivotal-lookingActive, not recruiting
NCT06540144 · 13 participants · Start Oct 8, 2024 · Primary completion Oct 5, 2027
Drug: rozanolixizumab · For: Generalized Myasthenia Gravis
Sites: Bologna, Italy; Milan, Italy; Naples, Italy · 9 sites in all
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04736706 · 1,688 participants · Start Apr 14, 2021 · Primary completion Feb 4, 2026
Drug: Pembrolizumab; Belzutifan and 2 more · For: Carcinoma, Renal Cell
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 262 sites in all
- A Phase 3 Study of NTLA-2001 in ATTRv-PNPivotal-lookingActive, not recruiting
Intellia TherapeuticsIndustry
NCT06672237 · 67 participants · Start Nov 22, 2024 · Primary completion Jul 2027
Drug: nexiguran ziclumeran; Normal Saline as Placebo · For: Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease and 17 more
Sites: Buenos Aires, Argentina; San Juan Bautista, Argentina; Campinas, Brazil · 14 sites in all
- Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS SymptomsPivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT04856982 · 158 participants · Start May 17, 2021 · Primary completion Aug 7, 2027
Drug: Tofersen; Placebo · For: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Sites: Scottsdale, Arizona; La Jolla, California; San Francisco, California · 32 sites in all
- An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisPivotal-lookingActive, not recruiting
TG Therapeutics, Inc.Industry
NCT04130997 · 1,100 participants (planned) · Start Nov 18, 2019 · Primary completion May 31, 2032
Drug: Ublituximab · For: Relapsing Multiple Sclerosis (RMS)
Sites: Pasadena, California; Denver, Colorado; Miami, Florida · 86 sites in all
- Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisPivotal-lookingActive, not recruiting
argenxargenx (ARGX)
NCT04833894 · 15 participants · Start Oct 26, 2021 · Primary completion Mar 2027
Drug: Efgartigimod IV · For: Generalized Myasthenia Gravis
Sites: Chicago, Illinois; Chapel Hill, North Carolina; Charlottesville, Virginia · 25 sites in all
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05070858 · 288 participants · Start Dec 14, 2021 · Primary completion Jul 8, 2025
Drug: Pozelimab + Cemdisiran; Cemdisiran and 1 more · For: Generalized Myasthenia Gravis
Sites: Scottsdale, Arizona; Irvine, California; Los Angeles, California · 116 sites in all
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05269004 · 1,300 participants (planned) · Start May 3, 2022 · Primary completion Dec 31, 2027
Drug: Ocrelizumab · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Laguna Hills, California; Palo Alto, California · 232 sites in all
- A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Pivotal-lookingActive, not recruiting
Longboard PharmaceuticalsIndustry
NCT06660394 · 108 participants · Start Sep 25, 2024 · Primary completion Dec 31, 2026
Drug: LP352; Placebo · For: Dravet Syndrome
Sites: Little Rock, Arkansas; Los Angeles, California; Palo Alto, California · 105 sites in all
- A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent MigrainePivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06616194 · 636 participants (planned) · Start Nov 15, 2024 · Primary completion Feb 26, 2030
Drug: Rimegepant; Placebo · For: Migraine
Sites: Phoenix, Arizona; Long Beach, California; Aurora, Colorado · 102 sites in all
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03711032 · 1,397 participants (planned) · Start Dec 24, 2018 · Primary completion Jul 31, 2028
Drug: Pembrolizumab; BCG · For: High-risk Non-muscle Invasive Bladder Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 209 sites in all
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
TG Therapeutics, Inc.Industry
NCT07211633 · 360 participants (planned) · Start Jul 9, 2025 · Primary completion Oct 31, 2026
Drug: Ublituximab; Ublituximab · For: Relapsing Multiple Sclerosis
Sites: Banja Luka, Bosnia and Herzegovina; Bihać, Bosnia and Herzegovina; Mostar, Bosnia and Herzegovina · 48 sites in all
- Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseasePivotal-lookingActive, not recruiting
Actinogen MedicalIndustry
NCT06125951 · 247 participants · Start Apr 12, 2024 · Primary completion Sep 22, 2026
Drug: Xanamem; Placebo · For: Dementia Moderate; Dementia, Mild; Alzheimer Disease
Sites: Carlsbad, California; Sherman Oaks, California; Denver, Colorado · 34 sites in all
- A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromePivotal-lookingActive, not recruiting
Stoke Therapeutics, IncIndustry
NCT06872125 · 170 participants (planned) · Start Jun 4, 2025 · Primary completion Mar 2027
Drug: zorevunersen · For: Dravet Syndrome
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 61 sites in all
- A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Pivotal-lookingActive, not recruiting
Vor BiopharmaIndustry
NCT06456580 · 191 participants · Start Jul 17, 2024 · Primary completion Mar 2027
Drug: Telitacicept; Placebo · For: Generalized Myasthenia Gravis
Sites: Scottsdale, Arizona; Los Angeles, California; Orange, California · 120 sites in all
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigrainePivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT03836040 · 457 participants · Start Jul 19, 2019 · Primary completion Nov 19, 2025
Drug: Erenumab Dose 1; Erenumab Dose 2 and 1 more · For: Migraine
Sites: Ann Arbor, Michigan; Saint-Nicolas, Belgium; Medellín, Colombia · 11 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.